VIOT Q4 2022 Earnings Losses Deepen Amid Challenging IoT Market BioXcel Therapeutics BTAI Q1 2026 Earnings EPS Misses Expectations as PreRevenue Biotech Focuses on Pipeline Progress SOTK Q1 2026 Earnings EPS Misses Estimates by 216 Stock Rises 39 Day One Biopharmaceuticals Q4 2025 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Pipeline ITW Q1 2026 Earnings EPS Beats Estimates Shares Edge Higher FNLC Q1 2026 Earnings EPS of 080 Reported Stock Edges Up Amid Sparse Disclosure